Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
IOVA

Prezzo Iovance Biotherapeutics Inc

IOVA
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-28 23:27 (UTC+8)

As of 2026-04-28 23:27, Iovance Biotherapeutics Inc (IOVA) is priced at $0, with a total market cap of $1,12B, a P/E ratio of -2,49, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 11,26M. Over the past 52 weeks, IOVA has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

IOVA Key Stats

Yesterday's Close$3
Market Cap$1,12B
Volume11,26M
P/E Ratio-2,49
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)0,97
Net Income (FY)-$390,97M
Revenue (FY)$263,50M
Earnings Date2026-05-07
EPS Estimate0,19
Revenue Estimate$77,83M
Shares Outstanding326,85M
Beta (1Y)0.764

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
SectorHealthcare
IndustryBiotechnology
CEOFrederick G. Vogt
HeadquartersSan Carlos,CA,US
Official Websitehttps://www.iovance.com
Employees (FY)975,00
Average Revenue (1Y)$270,25K
Net Income per Employee-$401,00K

Iovance Biotherapeutics Inc (IOVA) FAQ

What's the stock price of Iovance Biotherapeutics Inc (IOVA) today?

x
Iovance Biotherapeutics Inc (IOVA) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Iovance Biotherapeutics Inc (IOVA)?

x

What is the price-to-earnings (P/E) ratio of Iovance Biotherapeutics Inc (IOVA)? What does it indicate?

x

What is the market cap of Iovance Biotherapeutics Inc (IOVA)?

x

What is the most recent quarterly earnings per share (EPS) for Iovance Biotherapeutics Inc (IOVA)?

x

Should you buy or sell Iovance Biotherapeutics Inc (IOVA) now?

x

What factors can affect the stock price of Iovance Biotherapeutics Inc (IOVA)?

x

How to buy Iovance Biotherapeutics Inc (IOVA) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

IOVA
CFD
Fai trading

Hot Posts su Iovance Biotherapeutics Inc (IOVA)

SelfRugger

SelfRugger

04-19 18:34
![](https://img-cdn.gateio.im/social/moments-4dff14c84b-5912595968-8b7abd-d8d215) Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data ======================================================================= Neha Gupta Wed, February 18, 2026 at 10:41 AM GMT+9 2 min read In this article: IOVA +1.75% Iovance Biotherapeutics, Inc. (NASDAQ:**IOVA**) is **one of the best high-return penny stocks to buy right now**. On February 5, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced data affirming a best-in-class profile for commercial Amtagvi. ![](https://img-cdn.gateio.im/social/moments-e6d71ee01f-29bb64b788-8b7abd-d8d215) Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data The company is developing Amtagvi as a novel T cell therapy for advanced melanoma patients receiving anti-PD-1 and targeted therapies. Trial results presented at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) showed a higher response rate with Amtagvi treatment following 2 or fewer lines of therapy than the objective response rate. > Lilit Karapetyan, MD, MS of H. Lee Moffitt Cancer Center & Research Institute stated, “The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment.” An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy. > > According to Daniel Kirby, Chief Commercial Officer of Iovance, the impressive response rates, paired with five-year durability and survival data, affirm a best-in-class profile and better outcomes with Amtagvi in patients. The impressive results position the company to capitalize on an unmet medical need, whereby more than 8,000 people die annually as a result of advanced melanoma. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a biotechnology company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies to treat solid tumor cancers. By leveraging a patient’s own immune system, Iovance creates personalized cancer treatments—including FDA-approved Amtagvi for melanoma—that recognize and attack cancer cells. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the **best short-term AI stock**. **READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.** Disclosure: None. This article is originally published at **Insider Monkey**. Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0
SelfRugger

SelfRugger

04-08 02:40
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success ========================================================================================== Maham Fatima Fri, February 27, 2026 at 4:27 AM GMT+9 2 min read In this article: IOVA -1.96% Iovance Biotherapeutics Inc. (NASDAQ:**IOVA**) is one of the most promising penny stocks under $5 to buy. On February 24, Iovance Biotherapeutics reported earnings for Q4 and the full year 2025, highlighted by a 61% year-over-year increase in total annual revenue to $264 million. Q4 alone generated $87 million in product revenue, representing 30% growth over the previous quarter. This growth was largely driven by the success of Amtagvi, which saw a 112% increase in year-over-year revenue, alongside improved operational efficiency. On the clinical and regulatory front, Iovance achieved several milestones that support its long-term outlook. The FDA granted Fast Track Designation for lifileucel in non-small cell lung cancer, a move that validates current clinical data and supports a projected 2027 launch for that indication. Additionally, the company reported a promising 50% confirmed response rate in advanced soft tissue sarcomas, with data showing that patient responses are deepening over time. Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success While management did not provide specific revenue guidance for 2026, they expressed confidence in the company’s expanding pipeline and the gradual ramp-up of community-based Authorized Treatment Centers/ATCs to complement their established academic network. Looking ahead, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is preparing for international market launches and continued data readouts for its combination therapies. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the **best short-term AI stock**. **READ NEXT: ****30 Stocks That Should Double in 3 Years**** and ****11 Hidden AI Stocks to Buy Right Now****.** Disclosure: None. **Follow Insider Monkey on Google News****.** Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0
MrDecoder

MrDecoder

03-13 01:18
When a stock is in a seemingly endless tailspin, it can be tough to take a chance and invest in it. Even if its valuation seems enticing enough to take a position, there's always lingering worry about whether it will only end up falling further. While hitting a 52-week low may sound like shares have become a cheap buy, a new low could still be right around the corner. **Iovance Biotherapeutics** (IOVA 11.88%) has been hitting new lows this year, and it's down more than 75% in the past 12 months. Its performance has been downright abysmal. Although the company does have an approved treatment in its portfolio, there's still no shortage of risk for investors. Is there a reason to expect a turnaround for Iovance, or are you better off simply steering clear of this healthcare stock? Image source: Getty Images. Iovance shows progress in recent results ---------------------------------------- On Nov. 6, Iovance released its third-quarter earnings numbers, which sparked a rally of more than 20%. Revenue totaled $67.5 million, an increase of 13% year over year. Sales of its leading therapy Amtagvi, a cellular therapy for advanced melanoma, generated the lion's share of revenue at $58 million. The company also noted that its gross margin improved and is now around 43%. The problem is that the healthcare company still has a long way to go in getting to a break-even point. Its loss for third quarter totaled $91.3 million, which was higher than the $83.5 million loss that Iovance incurred in the same period last year. While its selling, general and administrative (SG&A) costs have decreased, the company has spent heavily on research and development (R&D), which at $75.2 million this past quarter was more than its top line. Could this be the start of a bigger rally for Iovance? ------------------------------------------------------ Investors clearly seemed pleased with the recent results, which gave Iovance's stock a much-needed boost. But it may take a lot more than just a single quarter to convince the market that it's a safe buy. The good news is that the company is still in the early stages of commercializing Amtagvi, which obtained approval from regulators in February 2024. This year is the first full year that Amtagvi has been on the market, and the company anticipates its top line will be between $250 million and $300 million. That's a considerable improvement from $164 million in 2024, and a huge step up from previous years when its revenue was zero. With much more growth on the way, Iovance could continue to win over more investors. Another positive: The company says that with around $307 million in cash and investments on its books as of the end of September, it believes it can fund its operations until at least the second quarter of 2027, which means there may not be a big need for cash infusions (causing dilution) in the near future. But any time there's a lack of profitability, cash burn is inevitably going to be a concern, because new share offerings can quickly cripple a stock. Expand NASDAQ: IOVA ------------ Iovance Biotherapeutics Today's Change (-11.88%) $-0.57 Current Price $4.26 ### Key Data Points Market Cap $2.0B Day's Range $4.20 - $4.74 52wk Range $1.64 - $5.63 Volume 311K Avg Vol 15M Gross Margin 17.09% Is Iovance a good stock to buy today? ------------------------------------- Iovance shares have crashed in the past year, but the business itself is moving in the right direction. Sales are growing and margins are improving. The market isn't being patient with the stock, and there's still plenty of risk here. If you have a high risk tolerance, however, you may want to consider taking a small position at this stage. This is an intriguing growth stock that a larger pharma company may end up acquiring in the future. And if Iovance is able to turn a profit and continue growing its sales, that could also lead to strong gains for investors down the road. Iovance Biotherapeutics isn't a stock that's for the faint of heart, and there are no assurances that it can't go lower, even after its sizable decline over the past year. But if you're OK with the risk and uncertainty, I think Iovance could make for an underrated buy right now.
0
0
0
0